Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Snap On Incorporated (SNA) vs GeneDx Holdings Corp (WGS) Price & Performance

Snap On IncorporatedTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Snap On Incorporated vs GeneDx Holdings Corp — how do they compare? Snap On Incorporated trades at $408.11 (market cap $21.30B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Snap On Incorporated is far larger — about 8.7× GeneDx Holdings Corp's market cap, and Snap On Incorporated pays a 2.37% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

SNAWGS
Market Cap
$21.30B$2.44B
Sector
TechnologyTechnology
52-Week High
$419.31$167.51
52-Week Low
$321.38$34.51
Enterprise Value
$20.93B$2.48B
Dividend Yield
2.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Snap On Incorporated

Snap-on Incorporated (SNA) trades at $407.78, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though valuation metrics appear elevated at P/E 21.01 and P/S 4.12. Recent Q2 2026 earnings beat expectations with $4.96 EPS, while the $100 million Diesel Laptops acquisition expands diagnostic capabilities.

SNA offers growth potential through strategic acquisitions and operational efficiency, with analyst consensus target of $455.33 suggesting 11.7% upside. Key risks include integration challenges from recent acquisitions and premium valuation pressure. The bullish technical setup combined with strong profitability supports a positive medium-term outlook despite near-term valuation concerns.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.

Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Snap On Incorporated

Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.

Read more on SNA

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS